Breakwater Archives

Potential new first-line treatment strategy for patients with BRAF V600E-mutant metastatic colorectal cancer

The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…

First-line treatment with dual-targeted therapies and chemotherapy doubles overall survival in patients with BRAF-mutated metastatic colorectal cancer

The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…

Potentially practice-changing results point to new standard-of -care treatments for patients with metastatic colorectal cancer

Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…